ChronoScale Corporation Common Stock (NASDAQ:CHRN) Stock Price Down 6.1% – Here’s Why

ChronoScale Corporation Common Stock (NASDAQ:CHRN) traded down 6.1% during trading on Wednesday . The stock traded as low as $19.78 and last traded at $19.78. Approximately 40,809 shares changed hands during mid-day trading, a decline of 83% from the average daily volume of 240,936 shares. The stock had previously closed at $21.06.

Analysts Set New Price Targets

Separately, Weiss Ratings raised ChronoScale Corporation Common Stock from a “sell (d-)” rating to a “sell (d)” rating in a research note on Monday, August 24th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus price target of $6.00.

ChronoScale Corporation Common Stock Trading Down 12.0%

The firm has a market cap of $2.70 billion, a price-to-earnings ratio of -3.45 and a beta of 0.98. The business has a 50 day moving average of $21.37 and a 200 day moving average of $16.64. The company has a quick ratio of 0.51, a current ratio of 0.51 and a debt-to-equity ratio of 0.06.

ChronoScale Corporation Common Stock (NASDAQ:CHRN) last released its earnings results on Wednesday, August 19th. The company reported ($0.12) earnings per share (EPS) for the quarter. The firm had revenue of $18.40 million during the quarter. ChronoScale Corporation Common Stock had a negative net margin of 135.66% and a negative return on equity of 197.81%. On average, research analysts forecast that ChronoScale Corporation Common Stock will post -0.1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On ChronoScale Corporation Common Stock

Large investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its position in shares of ChronoScale Corporation Common Stock by 68.9% in the fourth quarter. Geode Capital Management LLC now owns 25,212 shares of the company’s stock worth $218,000 after acquiring an additional 10,281 shares during the last quarter. Citadel Advisors LLC purchased a new stake in ChronoScale Corporation Common Stock during the third quarter valued at about $198,000. Shay Capital LLC purchased a new position in shares of ChronoScale Corporation Common Stock in the 3rd quarter worth about $67,000. Virtu Financial LLC purchased a new position in ChronoScale Corporation Common Stock in the third quarter valued at approximately $57,000. Finally, Roble Belko & Company Inc grew its stake in ChronoScale Corporation Common Stock by 104.5% during the first quarter. Roble Belko & Company Inc now owns 2,338 shares of the company’s stock worth $25,000 after buying an additional 1,195 shares during the period. 6.42% of the stock is currently owned by hedge funds and other institutional investors.

ChronoScale Corporation Common Stock Company Profile

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.